Polycystic ovary syndrome (PCOS) is an endocrine disorder characterized primarily by insulin resistance (IR), as well as hyperandrogenism and chronic anovulation [1]. PCOS is one of the most common endocrine disorders occurring in reproductive-aged women, with an estimated prevalence of between 4 and 6% [2]. Standard PCOS treatment entails insulin-sensitizing medications, such as biguanides (e.g., metformin) or peroxisome proliferator-activated receptors (PPAR) agonists (e.g., rosiglitazone, pioglitazone, and troglitazone) which generally results in improved metabolic and reproductive function in women with PCOS [3]. Depressive disorders are among the most common psychiatric diagnosis in America [4], and data indicate that women have double the lifetime risk of depression compared to men [4–7]. Mood disorders are the leading cause of disability among women aged 15–44 [8].
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Dunaif A. Current concepts in the polycystic ovary syndrome. Annu Rev Med 2001;52:401–419.
Franks S. Polycystic ovary syndrome. N Engl J Med 1995;333(13):853–861.
Dunaif A. The insulin-sensitizing agent troglitazone improves metabolic and reproductive abnormalities in the polycystic ovary syndrome. J Clin Endocrinol Metab 1996;81(9):3299–3306.
Kessler RC, McGonagle KA, Swartz M, Blazer DG, Nelson CB. Sex and depression in the National Comorbidity Survey. I: lifetime prevalence, chronicity and recurrence. J Affect Disord 1993;29(2–3):85–96.
Bebbington P, Dunn G, Jenkins R, et al. The influence of age and sex on the prevalence of depressive conditions: report from the National Survey of Psychiatric Morbidity. Psychol Med 1998;28(1):9–19.
Nolen-Hoeksema S. Sex differences in depression. Stanford: Stanford University Press; 1990.
Weissman MM. Cross-national epidemiology of major depression and bipolar disorder. JAMA 1996;276(4):293–299.
Murray CJL, Lopez AD. Alternative visions of the future: projecting mortality and disability, 1990–2020. In: Murray CJL, Lopez AD, eds. The Global Burden of Disease: A Comprehensive Assessment of Mortality and Disability from Diseases, Injuries, and Risk Factors in 1990 and Projected to 2020. Boston: Harvard University Press; 1996:325–395.
Rasgon NL, Rao RC, Hwang S, et al. Depression in women with polycystic ovary syndrome: clinical and biochemical correlates. J Affect Disord 2003;74(3):299–304.
Rasgon NL, Carter MS, Elman S, Bauer M, Love M, Korenman SG. Common treatment of polycystic ovarian syndrome and major depressive disorder: case report and review. Curr Drug Targets Immune Endocr Metabol Disord 2002;2(1):97–102.
Cooper B, Holmes C. Previous psychiatric history as a risk factor for late-life dementia: a population-based case-control study. Age Ageing 1998;27:181–188.
French LR, Schuman LM, Mortimer JA, Hutton JT, Boatman RA, Christians B. A case-control study of dementia of the Alzheimer type. Am J Epidemiol 1985;121(3):414–421.
Kokmen E, Beard CM, Chandra V, Offord KP, Schoenberg BS, Ballard DJ. Clinical risk factors for Alzheimer's disease: a population-based case-control study. Neurology 1991;41(9):1393–1397.
Shalat SL, Seltzer B, Pidcock C, Baker EL. Risk factors for Alzheimer's disease: a case-control study. Neurology 1987;37(10):1630–1633.
Speck CE, Kukull WA, Brenner DE, et al. History of depression as a risk factor for Alzheimer's disease. Epidemiology 1995;6(4):366–369.
Steffens DC, Plassman BL, Helms MJ, Welsh-Bohmer KA, Saunders AM, Breitner JC. A twin study of late-onset depression and apolipoprotein E epsilon 4 as risk factors for Alzheimer's disease. Biol Psychiatry 1997;41(8):851–856.
Wetherell JL, Gatz M, Johansson B, Pedersen NL. History of depression and other psychiatric illness as risk factors for Alzheimer disease in a twin sample. Alzheimer Dis Assoc Disord 1999;13(1):47–52.
Rasgon N, Jarvik GP, Jarvik L. Affective disorders and Alzheimer disease: a missing-link hypothesis. Am J Geriatr Psychiatry 2001;9(4):444–445.
Rasgon NL, Jarvik L. Insulin resistance, affective disorders, and Alzheimer's disease: review and hypothesis. J Gerontol A Biol Sci Med Sci 2004;59(2):178–183.
Weiner CL, Primeau M, Ehrmann DA. Androgens and mood dysfunction in women: comparison of women with polycystic ovarian syndrome to healthy controls. Psychosom Med 2004;66(3):356–362.
Elsenbruch S, Hahn S, Kowalsky D, et al. Quality of life, psychosocial well-being, and sexual satisfaction in women with polycystic ovary syndrome. J Clin Endocrinol Metab 2003;88(12):5801–5807.
Hollinrake E, Abreu A, Maifeld M, Van Voorhis BJ, Dokras A. Increased risk of depressive disorders in women with polycystic ovary syndrome. Fertil Steril 2007;87(6):1369–1376.
Klipstein KG, Goldberg JF. Screening for bipolar disorder in women with polycystic ovary syndrome: a pilot study. J Affect Disord 2006;91:205–209.
Kessler RC, Berglund P, Demler O, Jin R, Merikangas KR, Walters EE. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:593–602.
Radloff L. The CES-D Scale: a self-report depression scale for research in the general population. Appl Psych Meas 1977;1(3):385–401.
Baischer W, Koinig G, Hartmann B, Huber J, Langer G. Hypothalamic-pituitary-gonadal axis in depressed premenopausal women: elevated blood testosterone concentrations compared to normal controls. Psychoneuroendocrinology 1995;20(5):553–559.
Shulman LH, DeRogatis L, Spielvogel R, Miller JL, Rose LI. Serum androgens and depression in women with facial hirsutism. J Am Acad Dermatol 1992;27(2 Pt 1):178–181.
Weber B, Lewicka S, Deuschle M, Colla M, Heuser I. Testosterone, androstenedione and dihydrotestosterone concentrations are elevated in female patients with major depression. Psychoneuroendocrinology 2000;25(8):765–771.
Brantley PJ, Mehan DJJ, Thomas JL. The Beck Depression Inventory (BDI) and the Center for Epidemiologic Studies Depression scale (CES-D). In: Maruish MM, ed. Handbook of Psychological Assessment in Primary Care Settings. New Jersey: Lawrence Erlbaum Associates, Inc.; 1999.
Coyne JC, Schwenk TL. The relationship of distress to mood disturbance in primary care and psychiatric populations. J Consult Clin Psychol 1997;65(1):161–168.
Myers JK, Weissman MM. Use of a self-report symptom scale to detect depression in a community sample. Am J Psychiatry 1980;137(9):1081–1084.
Schulberg HC, Saul M, McClelland M, Ganguli M, Christy W, Frank R. Assessing depression in primary medical and psychiatric practices. Arch Gen Psychiatry 1985;42(12):1164–1170.
Oddens BJ, den Tonkelaar I, Nieuwenhuyse H. Psychosocial experiences in women facing fertility problems—a comparative survey. Hum Reprod 1999;14(1):255–261.
Williams KE, Marsh WK, Rasgon NL. Mood disorders and fertility in women: a critical review of the literature and implications for future research. Hum Reprod Update 2007;13(6):607–616.
Eggers S, Kirchengast S. The polycystic ovary syndrome--a medical condition but also an important psychosocial problem. Coll Antropol 2001;25(2):673–685.
Venkatesan AM, Dunaif A, Corbould A. Insulin resistance in polycystic ovary syndrome: progress and paradoxes. Recent Prog Horm Res 2001;56(1):295–308.
Pasquali R, Casimirri F. The impact of obesity on hyperandrogenism and polycystic ovary syndrome in premenopausal women. Clin Endocrinol 1993;39:1–16.
Kitzinger C. The thief of womanhood: women's experience of polycystic ovarian syndrome. Soc Sci Med 2002;54(3): 349–361.
Sills ES, Perloe M, Tucker M, Kaplan C, Genton M, Schattman G. Diagnostic and treatment characteristics of polycystic ovary syndrome: descriptive measurements of patient perception and awareness from 657 confidential self-reports. BMC Womens Health 2001;1(1):3.
Derogatis LR, Lipman RS, Covi L. SCL-90: an outpatient psychiatric rating scale--preliminary report. Psychopharmacol Bull 1973;9(1):13–28.
Henrich G. Questions on life satisfaction (FLZ M): a short questionnaire for assessing subjective quality of life. Eur J Psychol Assess 2000;16(3):150–159.
Ware Jr, JE, Sherbourne CD. The MOS 36-Item short-form health survey (SF-36): conceptual framework and item selection. Med Care 1992;30(6):473–483.
Lett HS, Blumenthal JA, Babyak MA, et al. Depression as a risk factor for coronary artery disease: evidence, mechanisms, and treatment. Psychosom Med 2004;66:305–315.
Gambineri A, Pelusi C, Vicennati V, Pagotto U, Pasquali R. Obesity and the polycystic ovary syndrome. Int J Obes 2002;26(7):883–896.
Flegal KL. Prevalence and trends in obesity among US adults, 1999–2000. JAMA 2002;288(14):1723–1727.
Ciaraldi TP, Morales AJ, Hickman MG, Odom-Ford R, Olefsky JM, Yen SS. Cellular insulin resistance in adipocytes from obese polycystic ovary syndrome subjects involves adenosine modulation of insulin sensitivity. J Clin Endocrinol Metab 1997;82(5):1421–1425.
Carmina E, Bucchieri S, Esposito A, et al. Abdominal fat quantity and distribution in women with polycystic ovary syndrome and extent of its relation to insulin resistance. J Clin Endocrinol Metab 2007;92(7):2500–2505.
Kirchengast S, Huber J. Body composition characteristics and body fat distribution in lean women with polycystic ovary syndrome. Hum Reprod 2001;16(6):1255–1260.
Puder JJ, Varga S, Kraenzlin M, De Geyter C, Keller U, Muller B. Central fat excess in polycystic ovary syndrome: relation to low-grade inflammation and insulin resistance. J Clin Endocrinol Metab 2005;90(11):6014–6021.
Lord J, Thomas R, Fox B, Acharya U, Wilkin T. The central issue? Visceral fat mass is a good marker of insulin resistance and metabolic disturbance in women with polycystic ovary syndrome. BJOG 2006;113(10):1203–1209.
Kiddy DS, Sharp PS, White DM, et al. Differences in clinical and endocrine features between obese and non-obese subjects with polycystic ovary syndrome: an analysis of 263 consecutive cases. Clin Endocrinol 1990;32(2):213–220.
Galtier-Dereure F, Pujol P, Dewailly D, Bringer J. Choice of stimulation in polycystic ovarian syndrome: the influence of obesity. Hum Reprod 1997;12 Suppl 1:88–96.
Larsson B, Bengtsson C, Bjorntorp P, et al. Is abdominal body fat distribution a major explanation for the sex difference in the incidence of myocardial infarction? the study of men born in 1913 and the study of women, Goteborg, Sweden. Am J Epidemiol 1992;135(3):266–273.
Ehrmann DA. Prevalence of impaired glucose tolerance and diabetes in women with polycystic ovary syndrome. Diabetes Care 1999;22(1):141–146.
Legro RS, Kunselman AR, Dodson WC, Dunaif A. Prevalence and predictors of risk for type II diabetes mellitus and impaired glucose tolerance in polycystic ovary syndrome: a prospective controlled study in 254 affected women. J Clin Endocrinol Metab 1999:165–169.
Dunaif A, Graf M, Mandeli J, Laumas V, Dobrjansky A. Characterization of groups of hyperandrogenic women with acanthosis nigricans, impaired glucose tolerance, and/or hyperinsulinemia. J Clin Endocrinol Metab 1987;65(3):499–507.
Sharp PS, Kiddy DS, Reed MJ, Anyaoku V, Johnston DG, Franks S. Correlation of plasma insulin and insulin-like growth factor-I with indices of androgen transport and metabolism in women with polycystic ovary syndrome. Clin Endocrinol 1991;35(3):253–257.
Legro RS, Kunselman AR, Dunaif A. Prevalence and predictors of dyslipidemia in women with polycystic ovary syndrome. Am J Med 2001;111(8):607–613.
Norman RJ, Masters L, Milner CR, Wang JX, Davies MJ. Relative risk of conversion from normoglycaemia to impaired glucose tolerance or non-insulin dependent diabetes mellitus in polycystic ovarian syndrome. Hum Reprod 2001;16(9): 1995–1998.
Solomon CG, Hu FB, Dunaif A, et al. Long or highly irregular menstrual cycles as a marker for risk of type 2 diabetes mellitus. JAMA 2001;286(19):2421–2426.
Cibula D, Cifkova R, Fanta M, Poledne R, Zivny J, Skibova J. Increased risk of non-insulin dependent diabetes mellitus, arterial hypertension and coronary artery disease in perimenopausal women with a history of polycystic ovary syndrome. Hum Reprod 2000;15(4):785–789.
Wild RA, Painter PC, Coulson PB, Carruth KB, Ranney GB. Lipoprotein lipid concentrations and cardiovascular risk in women with polycystic ovary syndrome. J Clin Endocrinol Metab 1985;61(5):946–951.
McLaughlin T, Reaven G, Abbasi F, Lamendola C, Saad M, Waters D, Simon J, Krauss RM. Is there a simple way to identify insulin-resistant individuals at increased risk of cardiovascular disease? Am J Cardiol 2005;96:399–404.
McLaughlin T, Abbasi F, Cheal K, Chu J, Lamendola C, Reaven G. Use of metabolic markers to identify overweight individuals who are insulin resistant. Ann Intern Med 2003;139(10):802–809.
Carlson L, Bottiger L, Ahfeldt P. Risk factors for myocardial infarction in the Stockholm prospective study: a 14-year follow-up focusing on the role of plasma triglycerides and cholesterol. Acta Med Scand 1979;206:351–360.
Castelli W, Garrison R, Wilson P, Abbott R, Kalonsdian S, Kannel W. Incidence of coronary heart disease and lipoprotein cholesterol levels: the Framingham Study. JAMA 1986;256:2385–2387.
Hokanson J, Austin M. Plasma triglyceride level is a risk factor for cardiovascular disease independent of high-density lipoprotein cholesterol level: a meta-analysis of population-based prospective studies. J Cardiovasc Risk 1996;3:213–219.
Miller G, Miller N. Plasma high-density-lipoprotein concentration and development of ischemic heart disease. Lancet 1975;1:16–19.
Benson S, Janssen OE, Hahn S, et al. Obesity, depression, and chronic low-grade inflammation in women with polycystic ovary syndrome. Brain Behav Immun 2008;22(2):177–184.
Diamanti-Kandarakis E, Paterakis T, Alexandraki K, et al. Indices of low-grade chronic inflammation in polycystic ovary syndrome and the beneficial effect of metformin. Hum Reprod 2006;21(6):1426–1431.
Cussons AJ, Stuckey BGA, Watts GF. Cardiovascular disease in the polycystic ovary syndrome: new insights and perspectives. Atherosclerosis 2006;185(2):227–239.
Orio F, Palomba S, Spinelli L, et al. The cardiovascular risk of young women with polycystic ovary syndrome: an observational, analytical, prospective case-control study. J Clin Endocrinol Metab 2004;89(8):3696–3701.
Paradisi G, Steinberg HO, Hempfling A, et al. Polycystic ovary syndrome is associated with endothelial dysfunction. Circulation 2001;103(10):1410–1415.
Tiras MB, Yalcin R, Noyan V, et al. Alterations in cardiac flow parameters in patients with polycystic ovarian syndrome. Hum Reprod 1999;14(8):1949–1952.
Vural B, Caliskan E, Turkoz E, Kilic T, Demirci A. Evaluation of metabolic syndrome frequency and premature carotid atherosclerosis in young women with polycystic ovary syndrome. Hum Reprod 2005;20(9):2409–2413.
Shaw LJ, Bairey Merz CN, Azziz R, et al. Postmenopausal women with a history of irregular menses and elevated androgen measurements at high risk for worsening cardiovascular event-free survival: results from the National Institutes of Health--National Heart, Lung, and Blood Institute sponsored women's ischemia syndrome evaluation. J Clin Endocrinol Metab 2008;93(4):1276–1284.
Solomon CG. Menstrual cycle irregularity and risk for future cardiovascular disease. J Clin Endocrinol Metab 2002;87(5):2013–2017.
Revised 2003 consensus on diagnostic criteria and long-term health risks related to polycystic ovary syndrome (PCOS). Hum Reprod 2004;19:41–47.
Pierpoint T, McKeigue PM, Isaacs AJ, Wild SH, Jacobs HS. Mortality of women with polycystic ovary syndrome at long-term follow-up. J Clin Epidemiol 1998;51(7):581–586.
Wild S, Pierpoint T, McKeigue P, Jacobs H. Cardiovascular disease in women with polycystic ovary syndrome at long-term follow-up: a retrospective cohort study. Clin Endocrinol 2000;52(5):595–600.
Battaglia C, Mancini F, Cianciosi A, et al. Vascular risk in young women with polycystic ovary and polycystic ovary syndrome. Obstet Gynecol 2008;111(2):385–395.
Meyer C, McGrath BP, Teede HJ. Overweight women with polycystic ovary syndrome have evidence of subclinical cardiovascular disease. J Clin Endocrinol Metab 2005;90(10):5711–5716.
Aleman A, Bronk E, Kessels RPC, Koppeschaar HPF, van Honk J. A single administration of testosterone improves visuospatial ability in young women. Psychoneuroendocrinology 2004;29(5):612–617.
Gouchie C, Kimura D. The relationship between testosterone levels and cognitive ability patterns. Psychoneuroendocrinology 1991;16(4):323–334.
Hausmann M, Slabbekoorn D, Van Goozen SH, Cohen-Kettenis PT, Gunturkun O. Sex hormones affect spatial abilities during the menstrual cycle. Behav Neurosci 2000;114(6):1245.
Moffat SD, Hampson E. A curvilinear relationship between testosterone and spatial cognition in humans: possible influence of hand preference. Psychoneuroendocrinology 1996;21(3):323–337.
Postma A, Meyer G, Tuiten A, van Honk J, Kessels RP, Thijssen J. Effects of testosterone administration on selective aspects of object-location memory in healthy young women. Psychoneuroendocrinology 2000;25(6):563–575.
Shute VJ, Pellegrino JW, Hubert L, Reynolds RW. The relationship between androgen levels and human spatial abilities. Bull Psychonomic Soc 1983;21(6):465–468.
Hogervorst E. Serum levels of estradiol and testosterone and performance in different cognitive domains in healthy elderly men and women. Psychoneuroendocrinology 2004;29(3):404–421.
Thilers PP, Macdonald SWS, Herlitz A. The association between endogenous free testosterone and cognitive performance: a population-based study in 35 to 90 year-old men and women. Psychoneuroendocrinology 2006;31(5):565–576.
Schattmann L, Sherwin BB. Testosterone levels and cognitive functioning in women with polycystic ovary syndrome and in healthy young women. Hormones and Behavior 2007;51(5):587–596.
Abbasi F, Brown B, Lamendola C, McLaughlin T, Reaven G. Relationship between obesity, insulin resistance, and coronary heart risk. J Am Coll Cardiol 2002;40:937–943.
Schattmann L, Sherwin BB. Effects of the pharmacologic manipulation of testosterone on cognitive functioning in women with polycystic ovary syndrome: a randomized, placebo-controlled treatment study. Hormones and Behavior 2007;51(5): 579–586.
Keettel WC, Bradbury JT, Stoddard FJ. Observations on the PCO syndrome. Am J Obstet Gynecol 1957;73:954–965.
Yen SS, Vela P, Rankin J. Inappropriate secretion of follicle stimulating hormone and luteinizing hormone in polycystic ovarian disease. J Clin Endocrinol Metab 1970;30:435–442.
Waldstreicher J, Santoro NF, Hall JE, Filicori M, Crowley WF. Hyperfunction of the hypothalamic pituitary axis in women with polycystic ovarian disease: indirect evidence for partial gonadotroph desensitization. J Clin Endocrinol Metab 1988;66:165–172.
Barnard L, Balen AH, Ferriday D, Tiplady B, Dye L. Cognitive functioning in polycystic ovary syndrome. Psychoneuroendocrinology 2007;32(8–10):906–914.
Potter GG, Steffens DC. Contribution of depression to cognitive impairment and dementia in older adults. Neurologist 2007;13(3):105–117.
Osei K. Insulin resistance and systemic hypertension. Am J Cardiol 1999;84(1A):33 J–36 J.
Cannon-Spoor HE, Levy JA, Zubenko GS, et al. Effects of previous major depressive illness on cognition in Alzheimer disease patients. Am J Geriatr Psychiatry 2005;13(4):312–318.
Alexopoulos GS, Meyers BS, Young RC, Mattis S, Kakuma T. The course of geriatric depression with “reversible dementia": a controlled study. Am J Psychiatry 1993;150(11):1693–1699.
Alexopoulos GS, Young RC, Meyers BS. Geriatric depression: age of onset and dementia. Biol Psychiatry 1993;34(3): 141–145.
Broe GA, Henderson AS, Creasey H, et al. A case-control study of Alzheimer's disease in Australia. Neurology 1990;40(11):1698–1707.
Buntinx F, Kester A, Bergers J, Knottnerus JA. Is depression in elderly people followed by dementia? A retrospective cohort study based in general practice. Age Ageing 1996;25(3):231–233.
Chen P, Ganguli M, Mulsant BH, DeKosky ST. The temporal relationship between depressive symptoms and dementia: a community-based prospective study. Arch Gen Psychiatry 1999;56(3):261–266.
Devanand DP, Sano M, Tang MX, et al. Depressed mood and the incidence of Alzheimer's disease in the elderly living in the community. Arch Gen Psychiatry 1996;53(2):175–182.
Geerlings MI, Schoevers RA, Beekman AT, et al. Depression and risk of cognitive decline and Alzheimer's disease. Results of two prospective community-based studies in The Netherlands. Br J Psychiatry 2000;176:568–575.
Reding M, Haycox J, Blass J. Depression in patients referred to a dementia clinic. A three-year prospective study. Arch Neurol 1985;42(9):894–896.
Ownby RL, Crocco E, Acevedo A, John V, Loewenstein D. Depression and risk for Alzheimer disease: systematic review, meta-analysis, and metaregression analysis. Arch Gen Psychiatry 2006;63(5):530–538.
Austin MP, Mitchell P, Goodwin GM. Cognitive deficits in depression: possible implications for functional neuropathology. Br J Psychiatry 2001;178:200–206.
Green RC, Cupples LA, Kurz A, et al. Depression as a risk factor for Alzheimer disease: the MIRAGE study. Arch Neurol 2003;60(5):753–759.
Kessing LV, Andersen PK. Does the risk of developing dementia increase with the number of episodes in patients with depressive disorder and in patients with bipolar disorder? J Neurol Neurosurg Psychiatry 2004;75(12):1662–1666.
Kessing LV, Nilsson FM, Siersma V, Andersen PK. Increased risk of developing diabetes in depressive and bipolar disorders? J Psychiatr Res 2004;38(4):395–402.
Palsson S, Aevarsson O, Skoog I. Depression, cerebral atrophy, cognitive performance and incidence of dementia. Population study of 85-year-olds. Br J Psychiatry 1999;174:249–253.
Arvanitakis Z, Wilson RS, Bienias JL, Evans DA, Bennett DA. Diabetes mellitus and risk of Alzheimer disease and decline in cognitive function. Arch Neurol 2004;61(5):661–666.
Kalmijn S, Feskens EJ, Launer LJ, Stijnen T, Kromhout D. Glucose intolerance, hyperinsulinaemia and cognitive function in a general population of elderly men. Diabetologia 1995;38(9):1096–1102.
Kilander L, Nyman H, Boberg M, Hansson L, Lithell H. Hypertension is related to cognitive impairment: a 20-year follow-up of 999 men. Hypertension 1998;31(3):780–786.
Kuusisto J, Koivisto K, Mykkanen L, et al. Essential hypertension and cognitive function. The role of hyperinsulinemia. Hypertension 1993;22(5):771–779.
Leibson CL, O'Brien PC, Atkinson E, Palumbo PJ, Melton LJ. Relative contributions of incidence and survival to increasing prevalence of adult-onset diabetes mellitus: a population-based study. Am J Epidemiol 1997;146(1):12–22.
Ott A, Stolk R, van Harskamp F, Pols HA, Hofman A, Breteler MM. Diabetes mellitus and the risk of dementia: the Rotterdam Study. Neurology 1999;53(9):1937–1942.
Peila R, Rodriguez BL, Launer LJ. Type 2 diabetes, APOE gene, and the risk for dementia and related pathologies: the Honolulu-Asia aging study. Diabetes 2002;51(4):1256–1262.
Stolk RP, Breteler MM, Ott A, et al. Insulin and cognitive function in an elderly population. The Rotterdam study. Diabetes Care 1997;20(5):792–795.
Vanhanen M, Koivisto K, Kuusisto J, et al. Cognitive function in an elderly population with persistent impaired glucose tolerance. Diabetes Care 1998;21(3):398–402.
Beeri MS, Silverman JM, Davis KL, et al. Type 2 diabetes is negatively associated with Alzheimer's disease neuropathology. J Gerontol A Biol Sci Med Sci 2005;60(4):471–475.
Steen E, Terry BM, Rivera EJ, et al. Impaired insulin and insulin-like growth factor expression and signaling mechanisms in Alzheimer's disease – is this type 3 diabetes? J Alzheimers Dis 2005;7(1):63–80.
Kuusisto J, Koivisto K, Mykkanen L, et al. Association between features of the insulin resistance syndrome and Alzheimer's disease independently of apolipoprotein E4 phenotype: cross sectional population based study. BMJ 1997;315(7115): 1045–1049.
Luchsinger JA, Tang M-X, Shea S, Mayeux R. Hyperinsulinemia and risk of Alzheimer disease. Neurology 2004;63(7): 1187–1192.
Gustafson D, Rothenberg E, Blennow K, Steen B, Skoog I. An 18-year follow-up of overweight and risk of Alzheimer disease. Arch Intern Med 2003;163(13):1524–1528.
Curb JD, Rodriguez BL, Abbott RD, et al. Longitudinal association of vascular and Alzheimer's dementias, diabetes, and glucose tolerance. Neurology 1999;52(5):971–975.
Kalmijn S, Foley D, White L, et al. Metabolic cardiovascular syndrome and risk of dementia in Japanese-American elderly men: the Honolulu-Asia aging study. Arterioscler Thromb Vasc Biol 2000;20(10):2255–2260.
McLaughlin T, Allison G, Abbasi F, Lamendola C, Reaven G. Prevalence of insulin resistance and associated cardiovascular disease risk factors among normal weight, overweight, and obese individuals. Metabolism 2004;53(4):495–499.
Petersen KF, Dufour S, Savage DB, et al. Inaugural Article: The role of skeletal muscle insulin resistance in the pathogenesis of the metabolic syndrome. Proc Natl Acad Sci 2007;104(31):12587–12594.
Author information
Authors and Affiliations
Corresponding author
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 2009 Springer Science+Business Media, LLC
About this chapter
Cite this chapter
Stemmle, P.G., Kenna, H.A., Rasgon, N.L. (2009). PCOS, Depression, and Alzheimer’s Disease. In: Farid, N.R., Diamanti-Kandarakis, E. (eds) Diagnosis and Management of Polycystic Ovary Syndrome. Springer, Boston, MA. https://doi.org/10.1007/978-0-387-09718-3_14
Download citation
DOI: https://doi.org/10.1007/978-0-387-09718-3_14
Published:
Publisher Name: Springer, Boston, MA
Print ISBN: 978-0-387-09717-6
Online ISBN: 978-0-387-09718-3
eBook Packages: MedicineMedicine (R0)